Retatrutide Pharmacokinetics: Half-Life, Absorption, and ADME

Overview

Retatrutide (LY3437943) is a synthetic acylated peptide developed by Eli Lilly that simultaneously activates the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GcgR). Its pharmacokinetic profile was engineered to permit once-weekly subcutaneous administration, a design goal achieved through fatty acid conjugation that dramatically extends circulating half-life relative to the native peptides it mimics.

The foundational pharmacology was described in Cell Metabolism (PMID 35985340), which reported the transition from discovery to first clinical proof of concept. Subsequent phase 1b multiple-ascending dose data published in The Lancet (PMID 36354040) and a dedicated phase 1 single-ascending dose study (NCT03841630) established the human PK parameters that inform clinical dosing.

Molecular Engineering for Extended Half-Life

Native GLP-1 has a plasma half-life of roughly 2 minutes because it is rapidly inactivated by dipeptidyl peptidase-4 (DPP-4) and cleared by renal filtration. Retatrutide circumvents both routes through two structural modifications:

1. C18 fatty diacid conjugation via a linker. The fatty acid tether enables reversible, high-affinity binding to serum albumin (approximately 67 kDa). Albumin-bound peptide is not filtered at the glomerulus, and the albumin-peptide complex is recycled via the neonatal Fc receptor (FcRn), further extending circulating time. This is the same general strategy used for semaglutide and the GIP/GLP-1 component of tirzepatide.

2. Aib (alpha-aminoisobutyric acid) substitutions. Aib residues at key positions create steric hindrance that slows DPP-4 cleavage, extending the intrinsic peptide stability before enzymatic degradation can occur.

The result, reported in the Cell Metabolism discovery paper (PMID 35985340), was a plasma half-life that supports once-weekly dosing, confirmed in humans by the phase 1b data (PMID 36354040).

flowchart TD
    A["Subcutaneous Injection\n(thigh / abdomen / upper arm)"] --> B["Lymphatic & capillary\nabsorption"]
    B --> C["Systemic Circulation\n(free + albumin-bound)"]
    C --> D1["GLP-1R activation\n(pancreas, CNS, gut)"]
    C --> D2["GIPR activation\n(pancreas, adipose)"]
    C --> D3["GcgR activation\n(liver, adipose, CNS)"]
    C --> E["FcRn-mediated\nalbumin recycling"]
    E --> C
    C --> F["Proteolytic catabolism\n(ubiquitous peptidases)"]
    F --> G["Amino acid fragments\n+ fatty acid metabolites"]
    G --> H["Renal & biliary\nexcretion"]
    style C fill:#e8f4f8,stroke:#2196F3
    style E fill:#fff3e0,stroke:#FF9800

Absorption

Route and Site of Injection

Retatrutide is formulated for subcutaneous (SC) injection. The phase 1b Lancet trial dosed participants via once-weekly SC injection across escalating dose cohorts (0.5 mg through 3/6/9/12 mg) over 12 weeks in adults with type 2 diabetes (PMID 36354040). The phase 2 obesity trial published in NEJM (NCT04881760) used doses escalating to 12 mg once weekly.

A dedicated phase 1 study (NCT05959096) enrolled 85 adults with BMI 27-45 kg/m² specifically to characterize relative bioavailability across three common SC injection sites: thigh, upper arm, and abdomen. Part A of that study measured AUC(0-inf) and Cmax from predose through 43 days post-injection. Part B included an intravenous reference arm (with a 71-day follow-up) to anchor absolute bioavailability estimates. Results from this study have not been publicly posted in the ClinicalTrials registry as of the publication date of this page.

Time to Maximum Concentration

Tmax was a secondary endpoint in both the phase 1 SAD study (NCT03841630) and the multi-site bioavailability study (NCT05959096). For acylated GLP-1 analogs conjugated via similar C18 fatty diacid chemistry, Tmax after subcutaneous injection typically falls in the range of 24-72 hours as the peptide moves through the lymphatic system and into the vascular compartment before reaching steady-state distribution. Specific median Tmax values for retatrutide have not been published in peer-reviewed literature as of this writing; full PK tables from the phase 1 studies remain in regulatory dossiers.

Dose Proportionality

The phase 1b multiple-ascending dose trial (PMID 36354040; NCT03841630) explicitly reported that pharmacokinetics were dose-proportional across the tested range. This means Cmax and AUC increase linearly with dose, simplifying exposure predictions when titrating from lower to higher doses in the clinical setting.

Distribution

Albumin Binding and Volume of Distribution

Albumin binding is the central determinant of retatrutide’s distribution profile. The C18 fatty diacid moiety has high affinity for the fatty acid binding sites on human serum albumin. When the majority of circulating drug is bound to albumin, the effective volume of distribution (Vd) is anchored close to the plasma volume and does not distribute extensively into tissues. This is consistent with the behavior of other long-acting fatty acid-acylated peptides: semaglutide, for example, has a Vd of approximately 12.5 liters in humans, close to plasma plus extracellular fluid of well-perfused compartments.

Specific Vd data for retatrutide have not been published in peer-reviewed form. The IV reference arm of NCT05959096 was designed in part to allow calculation of central volume of distribution from the IV concentration-time curve.

Central Nervous System Access

Functional data from preclinical models included in the Cell Metabolism discovery paper (PMID 35985340) showed that retatrutide reduced food intake through central mechanisms, consistent with CNS access by the intact peptide or via circumventricular organs that lack a complete blood-brain barrier. Central action at the hypothalamus and brainstem is well-established for GLP-1 agonists; the GcgR component adds additional CNS energy expenditure signaling.

Protein Binding and Free Fraction

Albumin binding of retatrutide is expected to exceed 99%, analogous to semaglutide (~99%). The small free fraction in plasma drives receptor engagement; the bound reservoir provides the extended half-life. Conditions that reduce albumin concentration (severe hepatic disease, nephrotic syndrome) could theoretically increase free drug fraction and alter exposure, which motivated the dedicated hepatic impairment PK study (NCT05916560).

Metabolism

Proteolytic Catabolism

Retatrutide does not undergo cytochrome P450 (CYP450)-mediated hepatic metabolism. As a peptide, it is catabolized by ubiquitous proteases and peptidases present throughout the body, including in the vasculature, kidney, liver, and intestinal mucosa. The Aib substitutions at DPP-4 recognition sites slow enzymatic cleavage, but the peptide backbone is ultimately degraded to constituent amino acids, which re-enter normal metabolic pools.

The C18 fatty diacid conjugate is released from the peptide backbone during catabolism. Fatty acid metabolites are handled through normal beta-oxidation and lipid metabolic pathways.

Drug-Drug Interaction Potential: CYP450

Because retatrutide is not a CYP substrate, inhibitor, or inducer, direct pharmacokinetic DDIs via CYP450 are not anticipated. The primary DDI concern is indirect: slowing of gastric emptying. GLP-1 receptor activation reduces gastric motility, which can delay the rate of absorption (reducing Cmax and prolonging Tmax) of orally administered drugs without substantially altering total exposure (AUC) in most cases.

The effect on metoprolol, a CYP2D6 substrate used as a pharmacokinetic probe for gastric emptying effects, was the focus of NCT06808802 (a phase 1 open-label sequential DDI study, completed April 2025). The design involved measuring metoprolol Cmax and AUC(0-inf) both before and after retatrutide administration. This is consistent with the regulatory pathway for GLP-1 agonists, where DDI assessment focuses on gastric emptying effects rather than enzyme-mediated interactions.

Elimination and Excretion

Plasma Half-Life

The plasma half-life of approximately 6 days is the defining pharmacokinetic feature of retatrutide. This was reported in the phase 1b Lancet trial (PMID 36354040) and cited in subsequent reviews (PMID 39724554). A 6-day half-life means:

• Once-weekly dosing achieves near-steady-state accumulation after approximately 4-5 doses (4-5 half-lives).
• Plasma concentrations remain above the pharmacologically active threshold between weekly doses.
• Drug washout after discontinuation takes approximately 4-5 weeks to reach <5% of steady-state trough concentration.

For comparison, semaglutide (once-weekly) has a half-life of approximately 7 days; tirzepatide (once-weekly) approximately 5 days. Retatrutide sits within this class range.

Renal Elimination

The intact peptide-albumin complex is not renally filtered due to the high molecular weight of albumin (approximately 67 kDa). Small proteolytic fragments and free fatty acid metabolites may appear in urine after catabolism. The ongoing phase 3 trial in participants with moderate-to-severe renal impairment (NCT06297603, TRANSCEND-T2D-3) will provide clinical data on whether renal function affects systemic exposure to the intact drug or its active fragments. No dose adjustment guidance is available at the time of publication.

Hepatic Elimination

The liver contributes to peptide catabolism but is not the primary elimination organ. The dedicated hepatic impairment study (NCT05916560) enrolled participants with mild, moderate, and severe hepatic dysfunction alongside healthy controls and measured single-dose AUC(0-inf) and Cmax through 30 days post-injection. The study completed in early 2025; results have not been published in peer-reviewed form or posted to ClinicalTrials.gov.

Steady-State Considerations

Accumulation Ratio

At once-weekly dosing with a 6-day half-life, the predicted accumulation ratio (steady-state AUC divided by single-dose AUC) is approximately 4-5x, as drug accumulates over successive doses until input and elimination reach equilibrium. This is pharmacokinetically expected and was implicitly acknowledged in the dose-escalation design of the phase 1b trial (PMID 36354040), which used gradual titration to manage tolerability as steady-state exposure increased with each dose tier.

Population Variability

Body weight, body composition, and injection site can influence SC absorption variability, which is why NCT05959096 specifically examined three injection sites in participants with elevated BMI. Obese individuals have increased subcutaneous adipose tissue depth and altered skin blood flow, both of which can affect absorption kinetics for SC biologics. No population PK model for retatrutide has been published as of this page’s publication date.

Summary Table

Key References

1. Rosenstock J, et al. “LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.” Lancet. 2022;400(10367):1869-1881. PMID 36354040. DOI 10.1016/S0140-6736(22)02033-5.

2. Coskun T, et al. “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.” Cell Metabolism. 2022;34(9):1234-1247. PMID 35985340. DOI 10.1016/j.cmet.2022.07.013.

3. Jastreboff AM, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity.” N Engl J Med. 2023;389(6):514-526. NCT04881760. DOI 10.1056/NEJMoa2301972.

4. Tetelbaun L, et al. “The First Triple Agonist for Antiobesity: Retatrutide.” Cardiol Rev. 2024. PMID 39724554.

5. Doggrell SA. “Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?” Expert Opin Investig Drugs. 2023;32(5):369-374. PMID 37086147.

6. ClinicalTrials.gov: NCT03841630 (Phase 1 SAD, healthy participants).

7. ClinicalTrials.gov: NCT05959096 (Absolute bioavailability, SC sites vs. IV, healthy high-BMI participants).

8. ClinicalTrials.gov: NCT05916560 (Hepatic impairment PK study).

9. ClinicalTrials.gov: NCT06808802 (DDI study: retatrutide and metoprolol).

10. ClinicalTrials.gov: NCT06297603 (TRANSCEND-T2D-3, renal impairment Phase 3).

See also

More on Retatrutide:

• Retatrutide research overview
• Retatrutide: Mechanism of action
• Retatrutide: Clinical & preclinical evidence
• Retatrutide: Safety profile
• Retatrutide: Dose-response

Related peptide family:

• GLP Family

Pathway context:

• Incretin Axis (GLP-1, GIP)

Head-to-head comparisons:

• Semaglutide vs Retatrutide
• Tirzepatide vs Retatrutide